Table 3.

Response outcomes following 12-week ADA treatment. Data are mean ± SD.

Variable	Joint^a and Skin^b Remission	Joint Remission Only^a	Skin Remission Only^b	Neither Skin nor Joint Remission^c
CRP, mg/dl	0.39 ± 0.62	0.54 ± 0.96	0.51 ± 1.02	0.66 ± 0.91
PtGA pain, VAS 0–100 mm	16.6 ± 20.7	14.7 ± 18.9	22.8 ± 21.0	36.2 ± 27.1
PtGA disease activity, VAS 0–100 mm	14.0 ± 18.7	15.9 ± 15.5	22.6 ± 19.9	38.7 ± 24.8
HAQ-DI	0.36 ± 0.49	0.35 ± 0.59	0.71 ± 0.63	0.78 ± 0.63

↵a TJC ≤ 1 + SJC ≤ 1.
↵b PGA = clear/almost clear.
↵c TJC > 1 + SJC > 1 + PGA > clear/almost clear. ADA: adalimumab; CRP: C-reactive protein; PtGA: patient’s global assessment; VAS: visual analog scale; HAQ-DI: Health Assessment Questionnaire–Disability Index; TJC: tender joint count; SJC: swollen joint count; PGA: physician’s global assessment.